Friedel, Evelyn B. N.
Tebartz van Elst, Ludger
Schäfer, Mirjam
Maier, Simon
Runge, Kimon
Küchlin, Sebastian
Reich, Michael
Lagrèze, Wolf A.
Kornmeier, Jürgen
Ebert, Dieter
Endres, Dominique
Domschke, Katharina
Nickel, Kathrin http://orcid.org/0000-0001-9863-317X
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Accepted: 15 December 2022
First Online: 23 December 2022
Declarations
:
: Evelyn B.N. Friedel: no conflict of interest, Ludger Tebartz van Elst: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics, Mirjam Schäfer: no conflict of interest, Simon Maier: no conflict of interest, Kimon Runge: no conflict of interest, Sebastian Küchlin: no conflict of interest, Michael Reich: no conflict of interest, Wolf A. Lagrèze: no conflict of interest, Jürgen Kornmeier: no conflict of interest, Dieter Ebert: no conflict of interest, Dominique Endres: no conflict of interest, Katharina Domschke: member of the ‘Steering Committee Neurosciences’, Janssen Pharmaceuticals, Inc., Kathrin Nickel: no conflict of interest.
: The study was approved by the Ethics Committee of the University Medical Center Freiburg (Approval ID: 314/18). All participants gave written informed consent to participate in the study.